A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymphnode (N) staging per AJCC 8th edition criteria as assessed by the investigator basedon radiological and/or clinical assessment:

• cT1c, N1-N2

• cT2, N0-N2

• cT3, N0-N2

• cT4a-d, N0-N2

• The participant must have a centrally confirmed diagnosis of BC that istriple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expressionin 1% to 10% cells and HER2-), as by the most recent American Society of ClinicalOncology (ASCO)/College of American Pathologists (CAP) guidelines.

• Provides a core needle biopsy from the primary breast tumor at screening to thecentral laboratory.

• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performedwithin 28 days before treatment randomization.

• Demonstrates adequate organ function.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement

• Has received any prior treatment, including radiation, systemic therapy,and/ordefinitive surgery for currently diagnosed breast cancer

• Has undergone excisional biopsy of the primary tumor, axillary lymph nodedissection, and/or axillary sentinel lymph node biopsy prior to study treatment.

• Received prior systemic anticancer therapy including investigational agents within 4weeks before randomization.

• Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or withan agent directed to another stimulatory or coinhibitory T-cell receptor (eg,CTLA-4, OX- 40, CD137).

• Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).

• Received prior treatment with a topoisomerase I inhibitor-containing ADC.

• Received a live or live-attenuated vaccine within 30 days before the first dose ofstudy intervention.

• Known additional malignancy that is progressing or has required active treatmentwithin the past 5 years.

• Uncontrolled systemic disease.

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease.